PIK3CA-Related Overgrowth Spectrum (PROS) Clinical Trials

20 clinical trials for PIK3CA-Related Overgrowth Spectrum (PROS) across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Proteus Syndrome and Related Congenital Disorders — RECRUITING
• A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) — RECRUITING · PHASE2
• EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) — RECRUITING · PHASE2
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM) — RECRUITING · PHASE1
• A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations — RECRUITING · PHASE2
• EPIK-P2: A PHASE II DOUBLE-BLIND STUDY WITH AN UPFRONT, 16-WEEK RANDOMIZED PLACEBO-CONTROLLED PERIOD, TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF ALPELISIB (BYL719) IN PEDIATRIC AND ADULT PATIENTS WITH PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) — RECRUITING · PHASE2
• Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. — NOT_YET_RECRUITING · PHASE2
• EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA Related-Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK-P1) — TERMINATED · PHASE2
• EPIK-P4: A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) — TERMINATED · PHASE2
• Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum — ACTIVE_NOT_RECRUITING · PHASE2
• EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) — TERMINATED · PHASE2
• Managed Access Programs for BYL719, Alpelisib — OTHER
• Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) — ACTIVE_NOT_RECRUITING · PHASE2
• National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) — COMPLETED
• A Study of the Epidemiology and Hospital Management of Patients With PROS in France — COMPLETED
• A PHASE 2 STUDY OF MUTANT-SELECTIVE PI3K INHIBITOR, RLY-2608, IN ADULTS AND CHILDREN WITH PIK3CA RELATED OVERGROWTH SPECTRUM AND MALFORMATIONS DRIVEN BY PIK3CA MUTATION — NOT_YET_RECRUITING · PHASE2
• Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study — COMPLETED
• Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib — COMPLETED
• Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies — TERMINATED
• Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation — COMPLETED · PHASE2

Refine this search